Legend Biotech Corporation (LEGN) has a negative trailing P/E of -11.4, meaning the company is currently unprofitable on a trailing twelve-month (TTM) basis. The forward P/E of 78.4 based on analyst estimates suggests a return to profitability is expected. Trailing earnings yield is -8.76%, forward earnings yield 1.28%. PEG 1.07.
Criteria proven by this page:
Overall SharesGrow Score: 58/100 with 3/7 criteria passed.
| Year | P/E (TTM) | PEG Ratio | P/B Ratio | P/S Ratio | Dividend Yield |
|---|---|---|---|---|---|
| 2017 | 521.5 | 0.00 | 401.47 | 207.01 | - |
| 2018 | -1,329.0 | 9.55 | 427.80 | 75.31 | - |
| 2019 | -48.1 | -0.01 | -39.75 | 79.03 | - |
| 2020 | -12.5 | -0.08 | 5.57 | 44.36 | - |
| 2021 | -16.3 | -2.46 | 8.57 | 95.39 | - |
| 2022 | -17.8 | -6.96 | 10.67 | 67.86 | - |
| 2023 | -20.4 | -4.42 | 8.47 | 37.16 | - |
| 2024 | -33.6 | 0.50 | 5.72 | 9.49 | - |
| 2025 | -13.5 | -0.21 | 4.00 | 3.88 | - |
| Year | EPS (Diluted) | Revenue | Net Income | Net Margin |
|---|---|---|---|---|
| 2017 | $0.14 | $23.59M | $9.37M | 39.7% |
| 2018 | $-0.06 | $49.13M | $-2.78M | -5.7% |
| 2019 | $-2.02 | $57.26M | $-132.97M | -232.2% |
| 2020 | $-5.14 | $75.68M | $-303.48M | -401% |
| 2021 | $-5.48 | $89.79M | $-386.21M | -430.1% |
| 2022 | $-5.62 | $117.01M | $-446.35M | -381.5% |
| 2023 | $-5.88 | $285.14M | $-518.25M | -181.8% |
| 2024 | $-1.94 | $627.24M | $-177.03M | -28.2% |
| 2025 | $-1.60 | $1.03B | $-297.58M | -28.8% |
| Year | EPS (Avg) | EPS Range | Revenue (Avg) | Revenue Range | Analysts |
|---|---|---|---|---|---|
| 2026 | $0.24 | $-0.14 – $0.36 | $1.43B | $1.36B – $1.56B | 4 |
| 2027 | $0.98 | $0.62 – $1.47 | $1.82B | $1.62B – $2.04B | 4 |
| 2028 | $1.72 | $1.46 – $1.98 | $2.12B | $2.12B – $2.12B | 1 |
| 2029 | $1.95 | $1.66 – $2.25 | $2.53B | $2.24B – $2.83B | 1 |
| 2030 | $2.13 | $1.82 – $2.46 | $2.77B | $2.45B – $3.09B | 1 |
